MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
PMID: 21876054
2011
Antimicrobial agents and chemotherapy
Abstract: It is also effective against INs that carry the three main RAL resistance mutations (Y143R, N155H, and to a lesser extent G140S-Q148H) and against the G118R mutant.
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
1Abstract: Viruses containing G118R and E138K remained largely susceptible to both RAL and EVG, suggesting a unique interaction between this second-generation INSTI and the enzyme may be defined by these residues as a potential basis for the increased intrinsic affinity and longer ""off"" rate of MK-2048."
Abstract: G118R also reduced viral replication capacity to approximately 1% that of the isogenic wild-type (wt) virus.
Abstract: G118R, which appeared first in cell culture, conferred low levels of resistance to MK-2048.
Abstract: Here, we report the identification of mutations (G118R and E138K) which confer resistance to MK-2048 and not to RAL or EVG.
HIV mutation literature information.
PMID: 
2011
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator